Brief: Poxel And Sumitomo Dainippon Pharma Announce Approval Of Twymeeg® For Treatment Of Type 2 Diabetes In Japan

Poxel SA

23/06/2021 07:37

June 23 (Reuters) - Sumitomo Dainippon Pharma Co Ltd
 4506.T :
    * POXEL AND SUMITOMO DAINIPPON PHARMA ANNOUNCE THE APPROVAL
OF
TWYMEEG® (IMEGLIMIN HYDROCHLORIDE) FOR THE TREATMENT OF TYPE 2
DIABETES IN JAPAN
    * TWYMEEG'S TARGET PRODUCT LAUNCH IS ANTICIPATED IN FISCAL
YEAR
2021
    * APPROVAL IN JAPAN TRIGGERS A JPY 1.75 BILLION
(APPROXIMATELY EUR
13.3 MILLION, USD 15.9 MILLION)(1) MILESTONE PAYMENT TO POXEL
FROM SUMITOMO DAINIPPON PHARMA
    * JAPANESE APPROVAL FOR TWYMEEG IS SUPPORTED BY POSITIVE
RESULTS
FROM PHASE 3 TIMES PROGRAM IN OVER 1,100 PATIENTS IN JAPAN

Source text for Eikon:  ID:nBwbCnDtta 
Further company coverage:  4506.T 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))